Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET

Company Participants

John Woolford - Investor Relations, Westwicke

Daniel O'Connell - President & Chief Executive Officer

Eric Siemers - Chief Medical Officer

Matt Zuga - Chief Financial Officer & Chief Business Officer

Conference Call Participants

Judah Frommer - Credit Suisse

Tom Shrader - BTIG

Ting Liu - UBS

Operator

Good day. Thank you for standing by, and welcome to the Acumen Pharmaceuticals, Second Quarter 2022 Update Call. At this time, all participants are in a listen-only mode. There'll be a brief overview followed by a question-and-answer session. [Operator Instructions] Today's call is being recorded.

And I would now like to turn the call over to John Woolford from Westwicke. Please go ahead.

John Woolford

Thank you, operator good afternoon. Thank you for joining us today to review Acumen’s second quarter 2022 update on operational progress and financial results. Before we start, we encourage you to read the operational and financial results press release issued this afternoon, which is accessible on our website in the Investors section.

Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. All these statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Our actual results could differ materially due to a number of factors, including the extent and duration of the effects of the COVID-19 pandemic, geopolitical events such as the conflict between Russia and Ukraine, related sanctions, macroeconomic conditions, such as risking inflation and uncertain credit and financial markets.

Please refer to our recent filings with the SEC for a full review of the risks and uncertainties associated with our business. Forward-looking statements speak only as of the date on which they are made and Acumen undertakes no obligation to update or revise any forward-looking statements.

Daniel O'Connell, President and Chief Executive Officer will begin today's call with a review select second quarter 2022 business highlights. Dr. Eric Siemers, Chief Medical Officer will then discuss the recent development in Alzheimer's disease field and provide an update on the ongoing INTERCEPT-AD trial. Finally, Matt Zuga, Chief Financial Officer and Chief Business Officer will provide a brief financial update. We will then open the call for Q&A.

I'll now hand the call over to Dan O'Connell, President and Chief Executive Officer. Dan?